Loading clinical trials...
Loading clinical trials...
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma
Conditions
Interventions
Eribulin mesylate 1.4 mg/m^2 intravenous
Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV
Locations
119
United States
Tucson, Arizona, United States
Los Angeles, California, United States
Orange, California, United States
Santa Monica, California, United States
Stanford, California, United States
Aurora, Colorado, United States
Start Date
March 10, 2011
Primary Completion Date
January 2, 2015
Completion Date
August 10, 2016
Last Updated
June 22, 2023
NCT07156565
NCT02701153
NCT07432932
NCT07222735
NCT06500065
NCT06797999
Lead Sponsor
Eisai Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions